KDR and neoplasm: Vatalanib (formerly PTK787/ZK 222584) is an oral protein kinase inhibitor (PTK) acting as angiogenesis inhibitor that is active against VEGFR and PDGFR tyrosine kinases, thereby offering a novel approach to inhibiting tumor growth [73].